Skip to content
Medical Health Aged Care

Clairvoyant Surpasses 50 Per Cent Randomization in its Phase 2b Psilocybin Therapy Trial for Alcohol Use Disorder

Clairvoyant Therapeutics 2 mins read

VANCOUVER, BC / ACCESSWIRE / November 29, 2023 / Clairvoyant Therapeutics Inc. (www.clairvoyantrx.com), the clinical-stage pharmaceutical company developing psilocybin therapy for alcohol use disorder (AUD), today announced that it has randomized more than 50 per cent of the expected 128 subjects for its 24-week Phase 2b clinical trial of synthetic psilocybin (25mg oral capsule). The double-blind, randomized controlled trial was initiated in October 2022 and is designed to assess multiple efficacy and safety endpoints.

"We are pleased that the pace of subject enrollment is at the upper end of our expectations. We are on track for an interim data read out in February 2024 and a top line read out in Q2 2024," stated Damian Kettlewell, CEO, Clairvoyant.

"Our goal is to be the first company in the world to obtain regulatory approval for the clinical use of psilocybin in AUD. The medical benefits of psychedelic compounds like psilocybin have been supressed for decades. We are pleased that regulatory authorities are now engaged in evidence-based approaches to review these potentially remarkable compounds."

Clairvoyant has been motivated to explore psilocybin therapy for AUD as a result of pioneering academic work by researchers in the U.S. Positive clinical results will support Clairvoyant's goal to help millions of AUD patients around the world.

Alcohol is the leading risk factor for overall burden of disease among men and a significant risk factor among women (source: WHO Global Status Report on Alcohol and Health 2014). A regional study recently reported that fewer than 5 per cent of patients diagnosed with moderate to severe alcohol use disorder receive recommended medications (source: BC Centre for Substance Use, 2023).

About Clairvoyant Therapeutics

Clairvoyant Therapeutics is a Canadian biotechnology company trailblazing a path to global mental health through psilocybin therapy. Clairvoyant's speed-to-market clinical strategy is designed to enable psilocybin therapy in the EU, UK & Canada to treat patients living with Alcohol Use Disorder (AUD) beginning in 2026.

The company's exceptional team, with deep clinical development experience, has made Clairvoyant the most advanced company developing psilocybin therapy for the treatment of AUD. Clairvoyant is a member of Life Sciences BC.

Additional information about Clairvoyant's clinical trial may be found at ClinicalTrials.gov

-30-

For more information:
Damian Kettlewell
damian@clairvoyantrx.com

SOURCE: Clairvoyant Therapeutics



View source version on accesswire.com:
https://www.accesswire.com/810748/clairvoyant-surpasses-50-per-cent-randomization-in-its-phase-2b-psilocybin-therapy-trial-for-alcohol-use-disorder

More from this category

  • Government VIC, Medical Health Aged Care
  • 11/02/2025
  • 15:33
Foundation for Alcohol Research and Education

FARE supports Victorian Coroner’s calls for alcohol delivery reforms

The Foundation for Alcohol Research and Education (FARE) has supported Coroner Ingrid Giles’ call for reforms to the state’s alcohol laws today, including restrictions to the delivery of alcohol. Following the Inquest into the death of Victorian woman, Ms Kathleen Arnold, due to “alcohol toxicity in the context of chronic alcohol consumption,” the Coroner’s recommendations include: - prohibit home delivery of alcohol between 10pm and 10am. - require a minimum two-hour delay between order and dispatch of alcohol for home delivery. - develop a new Alcohol Action Plan or a program of work (including specific actions,timeframes, accountabilities, and public reporting…

  • Contains:
  • Medical Health Aged Care
  • 11/02/2025
  • 15:20
Royal Australian College of GPs

WA Liberals package a model for rebuilding GP access: RACGP

The Royal Australian College of GPs (RACGP) has praised today’s announcement of a package to increase Western Australians’ access to GPs and reduce hospital readmissions by the state opposition as parties in WA gear up for the 8 March election. The $140 million package includes $40,000 GP training incentive grants to grow WA’s specialist GP workforce, funding to give hospital-based junior doctors hands-on experience in accredited general practices, $60 million funding for patients to consult with a specialist GP following hospital discharge, and funding to upskill GPs in prescribing for ADHD. Several of these measures reflect solutions that have been…

  • Contains:
  • Medical Health Aged Care
  • 11/02/2025
  • 14:00
Dementia Australia

Allied health support is key for quality dementia care

Dementia Australia, Occupational Therapy Australia and Speech Pathology Australia have today called for people living with dementia to have access to pathways of allied…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.